EP1773328A1 - Produit d'hygiene intime prebiotique - Google Patents

Produit d'hygiene intime prebiotique

Info

Publication number
EP1773328A1
EP1773328A1 EP05767884A EP05767884A EP1773328A1 EP 1773328 A1 EP1773328 A1 EP 1773328A1 EP 05767884 A EP05767884 A EP 05767884A EP 05767884 A EP05767884 A EP 05767884A EP 1773328 A1 EP1773328 A1 EP 1773328A1
Authority
EP
European Patent Office
Prior art keywords
acid
substance
use according
candida
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05767884A
Other languages
German (de)
English (en)
Inventor
Dirk Bockmühl
Heide-Marie Höhne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP1773328A1 publication Critical patent/EP1773328A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Definitions

  • the cosmetic treatment of the vaginal region is always associated with an influence on the vaginal flora.
  • the use of surfactant products may weaken the bacterial flora of lactobacilli and bifidobacteria to such an extent that they can no longer perform their natural protective function.
  • the result may be vaginal infections, especially with the yeast Candida albicans.
  • the active ingredient or combination of active substances promotes the growth of the desired skin germs and at the same time reduces the presence of the unwanted hyphae form of Candida.
  • this drug combination causes firstly a promotion of Laktobazillen- and Bifidobakterienflora and thus a regeneration of the protective vaginal bacteria. Secondly, the reduction of Candida adhesion to vaginal epithelial cells additionally supports the establishment of lactobacilli and bifidobacteria. On the other hand, since an increased occurrence of protective bacteria represses the growth of Candida, the combination of the two active ingredients can produce a true synergistic effect.
  • the substances which reduce the hyphenation of Candida and / or are anti-adhesively active selected from Dufstoffalkoholen, propolis extracts, plant extracts and / or terpenes and derivatives thereof.
  • the terpenes are selected from terpene alcohols, ie such terpenes, preferably mono-, sesqui- and / or diterpenes bearing a free hydroxyl group. Citronellols, geraniol, farnesol and patchouli alcohol are particularly preferred.
  • the perfume alcohols are selected from eugenol, cinnamyl alcohol and anethole, in particular eugenol.
  • Fucoidin also known as fucosidan or fucoidan, is a polysaccharide of brown algae (Fucus vesiculosus, bladderwrack) consisting mainly of sulfated L-fucose in 1,2- ⁇ -glycosidic linkage.
  • brown algae Flucus vesiculosus, bladderwrack
  • hyphal formation of Candida albicans is significantly reduced while at the same time not affecting cell growth.
  • the carrier-bound form in another preferred embodiment according to the invention is esters of perfume alcohols and / or terpenes with polymers.
  • polyacrylic acid polyacrylic acid esters, polymethacrylic acid, polymethacrylic acid esters, and
  • substances which reduce candida adhesion use substances which reduce the hyphae formation of candida, their concentration being chosen such that they do not act fungicidal (fungicidal) or fungistatic (fungus growth-inhibiting) at the point of application ,
  • a particular advantage of this embodiment is that the risk of resistance to the substances used is relatively low, since the fungi are neither killed nor their growth inhibited.
  • propolis extracts have Candida albicans minimum inhibitory concentrations (the lowest concentration of the substance preventing proliferation of the fungus) of 0.12% by weight and greater (Hegazi, Z. Naturforsch. 55c, 70-75 ( 2000)). These minimum inhibitory concentrations can be readily determined in a manner known to those skilled in the art.
  • the oligosugar is inulin or a derivative thereof and the plant extract containing the oligosugar is an inulin-containing plant extract, in particular selected from extracts of dahlia tubers, artichokes, Jerusalem artichoke tubers, chicory roots (Cichorium intybus), dandelion roots and from extracts of daisy family (Asteraceae), in particular Inula, or mixtures thereof.
  • the usable derivatives of inulin reference is explicitly made to the disclosure of WO 02/00188.
  • Further plant extracts suitable according to the invention are tea extracts, in particular from the family of the Theaceae or from the family of the Malvaceae, as well as extracts from the family of the Vitaceae.
  • the extract of the family of Theaceae is preferably an extract of Camellia spec, especially an extract of white tea ⁇ Camellia sinensis).
  • this is an extract from the leaves, as obtainable, for example, from Cosmetochem (Germany).
  • the extract of the Vitaceae family is preferably an extract of Vitis spec, in particular an extract of the grape (Vitis viticola). This is particularly preferably an extract of grape seeds.
  • preservatives such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof and liposomes or components thereof can also be used as carriers.
  • the pharmaceutical or cosmetic preparations are those for topical application to the skin and its appendages and / or for application to the mucous membrane, in particular in the vaginal and / or intestinal region.
  • these preparations are also called skin treatment agents.
  • the pH of the preparation is preferably between pH 5 and 7, more preferably between pH 5 and 6.
  • the cosmetic or pharmaceutical composition according to the invention may be any dosage form, for example a solid or liquid soap, a lotion, a powder, a spray, an aerosol, a foam, a tincture, a stick preparation, a cream, a gel , one Emulsion, a cleaning fluid or cleansing milk, a deodorant, an antiperspirant, an ointment, a hair conditioner or a shampoo and it may also be contained in any of the described or other dosage forms, for example in a plaster, in particular in a gel reservoir or matrix patch ,
  • the skin or mucous membrane in the vaginal area and in the testinal area can be considered as the site of application.
  • all physical areas that are naturally populated by lactobacilli and bifidobacteria and in which there is a risk of unwanted colonization by Candida come into question.
  • the composition contains, in addition to at least one plant extract to be used according to the invention in a prebiotic active ingredient combination, at least one further plant extract.
  • This further plant extract can be prepared, for example, by extraction of the entire plant, but also exclusively by extraction from flowers and / or leaves and / or seeds and / or other parts of plants.
  • extracting agent for the production of said further plant extracts for example water, alcohols and mixtures thereof can be used, as well as for the preparation of the prebiotic plant extracts.
  • alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol, propylene glycol and butylene glycol both as sole extractant and in admixture with water, are preferred.
  • Plant extracts based on water / propylene glycol in the ratio 1: 10 to 10: 1 have proven to be particularly proved suitable.
  • the steam distillation according to the invention falls under the preferred extraction method. If appropriate, the extraction can also be carried out in the form of dry extraction.
  • the cosmetic or pharmaceutical compositions of the invention may further contain fatty substances.
  • Fatty substances include fatty acids, fatty alcohols, natural and synthetic cosmetic oil components. and natural and synthetic waxes which may be in solid or liquid form in aqueous or oily dispersion.
  • stearic acid particularly preferred is the use of stearic acid.
  • the fatty acids used can carry one or more hydroxyl groups. Preferred examples of these are the ⁇ -hydroxy-C 8 -C 8 -carboxylic acids and 12-hydroxystearic acid.
  • the amount used is 0.1 to 15 wt .-%, preferably 0.5 to 10 wt .-%, particularly preferably 1 to 5 wt .-%, each based on the total composition.
  • fatty alcohols it is possible to use saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 6 to 30, preferably 10 to 22 and very particularly preferably 12 to 22 carbon atoms. Applicable according to the invention are e.g.
  • petrolatum paraffin waxes
  • Microwaxes of polyethylene or polypropylene and polyethylene glycol waxes It may be advantageous to use hydrogenated or hardened waxes.
  • chemically modified waxes especially the hard waxes, z. B. Montan ⁇ ester waxes, Sasol waxes and hydrogenated jojoba waxes, can be used.
  • Natural, chemically modified and synthetic waxes may be used alone or in combination.
  • the wax components are present in an amount of from 0.1 to 40% by weight, based on the total composition, preferably from 1 to 30% by weight and in particular from 5 to 15% by weight.
  • the monoalkyl ethers of glycerol ethylene glycol, 1, 2-propylene glycol or 1, 2-butanediol, from dialkyl ethers each having 12 - 24 carbon atoms, eg.
  • alkyl methyl ether or di-n-alkyl ethers each having a total of 12 to 24 carbon atoms, in particular di-n-octyl ether (Cetiol ® OE ex Cognis), as well as adducts of ethylene oxide and / or propylene oxide to mono- or polyvalent C 3 - 2 o-alkanols such as butanol and glycerol, z.
  • cyclic 1, 3-di- (2-ethyl-hexyl) -cyclohexane (Cetiol ® S), as well as volatile and nonvolatile silicone oils, the cyclic, such as.
  • decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane or may be linear, e.g. As linear dimethylpolysiloxane, commercially available z.
  • compositions of the invention may further comprise at least one hydrophilic modified silicone. They allow the formulation of highly transparent compositions, reduce the stickiness and leave a fresh feeling on the skin.
  • Hydrophilically modified silicones are understood according to the invention to mean polyorganosiloxanes having hydrophilic substituents which cause the water solubility of the silicones. According to the invention is understood to mean water-solubility that is at least 2 wt .-% resolve the modified with hydrophilic groups silicone in water at 20 0 C.
  • Corresponding hydrophilic substituents are, for example, hydroxy, polyethylene glycol or polyethylene glycol / polypropylene glycol side chains and ethoxylated ester side chains.
  • Sterols are understood to mean a group of steroids which have a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are beta-sitosterol, stigmasterol, campesterol and ergosterol. From mushrooms and yeasts sterols, the so-called mycosterols, isolated.
  • - Phospholipids especially the glucose phospholipids, the z. B. as lecithins or phosphatidylcholines from z. Egg yolks or plant seeds (eg soybeans),
  • polyglycerols and polyglycerol preferably Polyglyceryl-2 dipolyhydroxystearate (Dehymuls ® PGPH commercial product) and polyglyceryl-3-diisostearate (Lameform ® TGI commercial product)
  • At least one ionic emulsifier selected from anionic, zwitterionic, ampholytic and cationic emulsifiers.
  • Preferred anionic emulsifiers are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic acid monoalkylpolyoxyethyl ester with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups, monoglyceride sulfates, alkyl and alkenyl ether phosphates and protein fatty acid condensates.
  • Zwitterionic emulsifiers carry at least one quaternary ammonium group and at least one -COO " or -SO 3 ' group in the molecule
  • Particularly suitable zwitterionic emulsifiers are the so-called betaines such as the N-alkyl-N, N-dimethylammonium glycinates, N-acyl aminopropyl-N, N-dimethylammonium glycinates and 2-alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines having in each case 8 to 18 C atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • Ampholytic emulsifiers contain, in addition to a C 8 -C 24 -alkyl or -acyl group, at least one free amino group and at least one -COOH or -SO 3 H group in the molecule and can form internal salts.
  • the ionic emulsifiers are contained in an amount of 0.01 to 5 wt .-%, preferably from 0.05 to 3 wt .-% and particularly preferably from 0.1 to 1 wt .-%, based on the total agent ,
  • R 1 CO is a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22 carbon atoms
  • R 2 is hydrogen or methyl
  • R 3 represents linear or branched alkyl radicals having 1 to 4 carbon atoms and x represents numbers from 1 to 20,
  • Adducts of ethylene oxide with fatty acid alkanolamides and fatty amines Adducts of ethylene oxide with fatty acid alkanolamides and fatty amines
  • Cu-alkyl groups mainly of Ce to C 6 alkyl groups or substantially of C 12 - - Particularly preferred alkyl polyglycosides are those in which R consists essentially of Ca and C-io alkyl groups essentially of 12 are C- to C 16 - alkyl groups.
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides.
  • sugars having 5 or 6 carbon atoms and the corresponding oligosaccharides are used, for example glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • the alkyl polyglycosides which can be used according to the invention contain on average from 1.1 to 5, preferably from 1.1 to 2.0, particularly preferably from 1.1 to 1.8, sugar units.
  • the alkoxylated homologs of said alkyl polyglycosides can also be used according to the invention. These homologs may contain on average up to 10 ethylene oxide and / or propylene oxide units per alkyl glycoside unit.
  • Zwitterionic surfactants surface-active compounds are suitable which have at least one quaternary ammonium group and at least one -COO ⁇ in the molecule - wear or -SO 3 W group.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines having in each case 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • R 1 CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, derived from fatty acids having from 6 to 22, preferably 12 to derive up to 18 carbon atoms, such as C 12 / 14- or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, particularly sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
  • Y _ CH - COOR 2 wherein X is H or a -CH 2 COOR group, Y is H or -OH, under the condition that Y is H when X-CH 2 COOR, R, R 1 and R 2 are independently Hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C 6 -C 18) alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C 6 -C 6 ) hydroxyalkylpolyols having 2 to 16 hydroxyl radicals are selected, provided that at least one of the groups R, R 1 or R 2 is a radical Z, esters of sulfosuccinic acid salt of the general formula (IV),
  • R 1 and R 2 independently of one another denote a hydrogen atom, an alkali metal or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of the United ⁇ etherten (C 6 -C 8) -Alkylpolysaccharide having 1 to 6 monomeric units Saccharidein ⁇ and / or etherified aliphatic (C 6 -C 16) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals is selected, with the proviso that at least one Groups R 1 or R 2 is a radical Z,
  • Acyl taurates having a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds,
  • Acyl isethionates having a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds,
  • R 8 CO is a linear or branched acyl radical having 6 to 22 carbon atoms, x, y and z in total for O or for numbers from 1 to 30, preferably 2 to 10, and X is an alkali or alkaline earth metal.
  • monoglyceride (ether) sulfates suitable for the purposes of the invention are the reaction products of lauric acid monoglyceride, coconut fatty acid monoglyceride, palmitic acid monoglyceride, stearic acid monoglyceride, oleic acid monoglyceride and tallow fatty acid monoglyceride and their ethylene oxide adducts with sulfur trioxide or chlorosulfonic acid in the form of their sodium salts.
  • Monoglyceride sulfates of the formula (VI) in which R 8 CO is a linear acyl radical having 8 to 18 carbon atoms are preferably used.
  • compositions according to the invention may contain at least one protein hydrolyzate or its derivative.
  • Both vegetable and animal protein hydrolysates can be used according to the invention.
  • Animal protein hydrolysates are z.
  • Vegetable protein hydrolysates eg. Soy, wheat, almonds, peas, potato and rice protein hydrolysates.
  • Corresponding commercial products are z. B. DiaMin® ® (Diamalt) Gluadin ® (Cognis), Lexein ® (Inolex) and Crotein ® (Croda).
  • compositions according to the invention are the protein hydrolysates and their derivatives or the amino acids and their derivatives in amounts of up to 10 wt .-%, based on the total agent included. Amounts of from 0.1 to 5% by weight, in particular from 0.1 to 3% by weight, are particularly preferred.
  • compositions according to the invention may contain at least one mono-, oligo- or polysaccharide or derivatives thereof.
  • suitable monosaccharides are z.
  • glucose fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose and talose, the deoxy sugars fucose and rhamnose and amino sugars such.
  • glucosamine or galactosamine Preferred are glucose, fructose, galactose, arabinose and fucose; Glucose is particularly preferred.
  • suitable oligosaccharides are composed of two to ten monosaccharide units, for.
  • sucrose lactose or trehalose.
  • a particularly preferred oligosaccharide is sucrose.
  • honey which contains predominantly glucose and sucrose.
  • Polysaccharides which are suitable according to the invention are composed of more than ten monosaccharide units.
  • Preferred polysaccharides are the starches made from ⁇ -D-glucose units and starch degradation products such as amylose, amylopectin and dextrins.
  • Particularly advantageous according to the invention are chemically and / or thermally modified starches, for. Hydroxypropyl starch phosphate, dihydroxypropyldistarch phosphate or the commercial products Dry Flo® .
  • dextrans and their derivatives eg. B. dextran sulfate.
  • nonionic cellulose derivatives such as methylcellulose, hydroxypropylcellulose or hydroxyethylcellulose, and also cationic cellulose derivatives, z.
  • polysaccharides from fucose units e.g. B. the commercial product Fucogel ® .
  • Particularly preferred are the polysaccharides composed of amino sugar units, in particular chitins and their deacetylated derivatives, the chitosans, and mucopolysaccharides.
  • the inventively preferred mucopolysaccharides include hyaluronic acid and its derivatives, e.g. As sodium hyaluronate or Dimethylsilanolhyaluronat, and chondroitin and its derivatives, for. B. chondroitin sulfate.
  • compositions at least one film-forming, emulsion-stabilizing, thickening or adhesive polymer selected from natural and synthetic polymers which may be cationic, anionic, amphoteric or nonionic.
  • cationic polymers are polysiloxanes having quaternary groups, e.g. , The commercial products Q2-7224 (Dow Corning), Dow Corning ® 929 Emulsion (with amodimethicone), SM-2059 (General Electric), SLM-55067 (Wacker) and Abil ® -Quat 3270 and 3272 (Th. Goldschmidt).
  • Preferred anionic polymers which can support the action of the active ingredient used according to the invention comprise carboxylate and / or sulfonate groups and as monomers, for example, acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid.
  • the acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt.
  • Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.
  • Very particularly preferred anionic polymers contain 2-acrylamido-2-methylpropanesulfonic acid as the sole monomer or as comonomer, it being possible for the sulfonic acid group to be wholly or partly in salt form.
  • copolymers of at least one anionic monomer and at least one nonionic monomer are preferred.
  • anionic monomers reference is made to the substances listed above.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers.
  • a particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, the sulfonic acid groups being wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammo- nium salt present.
  • This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, Allylsucrose, AIIy Ipentaeryth rit and methylene-bisacrylamide are used.
  • crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, Allylsucrose, AIIy Ipentaeryth rit and methylene-bisacrylamide are used.
  • Such a polymer is contained in the commercial product Sepigel ® 305 from SEPPIC.
  • Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for. B. the commercial products Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidones z. B. under the trademark Luviskol ® (BASF) are sold.
  • compositions according to the invention may further contain at least one ⁇ -hydroxycarboxylic acid or ⁇ -ketocarboxylic acid or their ester, lactone or salt form.
  • Suitable ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids are selected from lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2-hydroxydodecanoic acid , 2-hydroxytetradecanoic acid, 2-hydroxyhexadecanoic acid, 2-hydroxyoctadecanoic acid, mandelic acid, 4-hydroxymandelic acid, malic acid, erythraric acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gular acid, 2-hydroxy-2-methylsuccinic
  • esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters.
  • the ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids or their derivatives are present in amounts of from 0.1 to 10% by weight, preferably 0.5 to 5% by weight, in each case based on the total composition.
  • compositions of the invention may contain other active ingredients, auxiliaries and additives, for example:
  • vitamin F which is understood as meaning essential fatty acids, especially linoleic acid, linolenic acid and arachidonic acid; - an ester of retinol (vitamin Ai) with a C 2 i 8 carboxylic acid, in particular retinyl acetate or retinyl palmitate.
  • Vitamins, provitamins or vitamin precursors of the vitamin B group or derivatives thereof and derivatives of 2-furanone in particular vitamin Bi (thiamine), vitamin B 2 (riboflavin), vitamin B 3 (nicotinic acid and / or nicotinic acid amide), vitamin B 5 ( Pantothenic acid and / or panthenol), vitamin B 6 (pyridoxine, pyridoxamine and / or pyridoxal) and / or vitamin B 7 (biotin),
  • catechins especially catechin and epicatechin, leucoanthocyanidins, catechin polymers (catechin tannins) and gallotannins,
  • - Thickener As gelatin, plant matter such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum or locust bean gum, natural and synthetic clays and Schicht ⁇ silicates, z. As bentonite, hectorite, montmorillonite or Laponite ® , fully synthetic hydrocolloids such. Polyvinyl alcohol, and also Ca, Mg or Zn soaps of fatty acids,
  • Alpha, beta and gamma cyclodextrins in particular for the stabilization of retinol,
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • MMP-1-inhibiting substances in particular selected from photolyase and / or T4 endonuclease V, propyl gallate, precocenes, 6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran and 3,4-dihydroxy 6-hydroxy-7-methoxy-2,2-dimethyl-1 (2H) -benzopyran,
  • Alumini ⁇ umchlorohydrate example powdery Micro Dry ® Ultrafine or distributed as in activated form as Reach ® 501 or Reach ® 103 from Reheis and in the form of aqueous solutions as Locron ® L of Clariant ® or as Chlorhydrol from Reheis. Under the name Reach ® 301, an aluminum sesquichlorohydrate offered by Reheis. Also, the use of aluminum-zirconium tri- or tetrachlorohydrex glycine complexes, which are, for example, from Reheis under the name Rezal 36G ® commercially, according to the invention is particularly advantageous.
  • the antiperspirant active may be present in the compositions of the invention, for example, in an amount of from 0.01 to 40% by weight, preferably from 2 to 30% by weight and in particular from 5 to 25% by weight, based on the amount of active substance in total Composition, included.
  • compositions of the invention may further contain deodorant agents and / or preservatives. Fragrance, antimicrobial, antibacterial or germ-inhibiting substances as well as enzyme-inhibiting substances, antioxidants and odor adsorbents are suitable according to the invention as deodorant active ingredients.
  • the deodorant agents, preservatives or antibacterial agents are preferably used in concentrations that do not lead to an unselective killing of the microflora in the genital area.
  • Inhibitors of lipases are preferred as enzyme-inhibiting substances.
  • arylsulfatases see WO 01/99376)
  • ⁇ -glucuronidases see WO 03/039505
  • 5- ⁇ -reductases are preferred as enzyme-inhibiting substances.
  • water-soluble polyols selected from water-soluble diols, triols and higher-grade alcohols and also polyethylene glycols.
  • diols are C 2 -Ci 2 diols, in particular 1, 2-propylene glycol, butylene glycols such as.
  • 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol pentanediols, z.
  • B. 1, 2-pentanediol, and hexanediols, for. B. 1, 6-hexanediol.
  • Deodorant or antiperspirant sticks may be in gelled, anhydrous wax base and based on W / O emulsions and O / W emulsions.
  • Gel sticks can be prepared on the basis of fatty acid soaps, dibenzylidenesorbitol, N-acylamino acid amides, 12-hydroxystearic acid and other gelling agents.
  • Aerosol sprays, pump sprays, roll on applications and creams can be used as water in oil emulsion, oil in water emulsion, silicone oil in water emulsion, water in oil microemulsion, oil in water.
  • compositions may be thickened, for example based on fatty acid soaps, dibenzylidenesorbitol, N-acylamino acid amides, 12-hydroxy stearic acid, carbomer and Carbopol type polyacrylates, polyacrylamides and polysaccharides, which may be chemically and / or physically modified.
  • the emulsions and microemulsions may be transparent, translucent or opaque.
  • Liquid and gelatin dosage forms of the compositions of the invention may contain thickening agents, e.g.
  • cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and methyl hydroxypropyl cellulose
  • thickening polymers based on polyacrylates which if desired can be crosslinked, for.
  • Carbopol types or Pemulen ® products or based on polyacrylamides or sulfonic acid-containing polyacrylates, eg. B Sepigel ® 305 or Simulgel® ® EG, also inorganic thickeners such. B. Bentonite and Hectorite (Laponite ®).
  • compositions of the invention may contain other cosmetically and dermatologically active substances, such as anti-inflammatory substances, solids selected from silicic acids, eg. As Aerosil ® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. B. talc, boron nitride, titanium dioxide, which may optionally be coated, optionally modified starches and starch derivatives, cellulose and polymer powders, further plant extracts, protein hydrolysates, vitamins, perfume oils, sebostatics, anti-acne agents and keratolytics.
  • solids selected from silicic acids, eg. As Aerosil ® types, silica gels, silica, clays, z. B. bentonite or kaolin, magnesium aluminum silicates, z. B. talc, boron nitride, titanium dioxide, which may optionally be coated, optionally modified starches and starch derivative
  • compositions according to the invention insofar as they are liquid, can be applied to flexible and absorbent carriers and offered as deodorant or antiperspirant wipes or sponges.
  • a flexible and absorbent carrier in the context of the invention, z.
  • textile fibers collagen or polymeric foams.
  • textile fibers both natural fibers such as cellulose (cotton, linen), silk, wool, regenerated cellulose (viscose, rayon), cellulose derivatives and synthetic fibers such as polyester, polyacrylonitrile, polyamide or Polyolefinfasem or mixtures of such fibers can be woven or unwoven. These fibers may be made into absorbent cotton pads, nonwovens or woven or knitted fabrics.
  • the substrate may have one, two, three and more than three layers, wherein the individual layers of the same or different materials can exist.
  • Each substrate layer may have a homogeneous or an inhomogeneous structure with, for example, different zones of different densities.
  • Absorbent for the purposes of the invention are those support substrates which, at 20 ° C., can bind at least 10% by weight, based on the dry weight, of water adsorptively or capillary.
  • the dosage form as an aerosol
  • the cosmetic composition containing a propellant selected from propane, butane, isobutane, pentane, isopentane, dimethyl ether, fluorohydrocarbons and chlorofluorocarbons.
  • a compressed propellant such as air, nitrogen or carbon dioxide can be used.
  • mixtures of the stated blowing agents can be used.
  • compositions according to the invention are in the form of a liquid or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, microemulsion, PIT emulsion or Pickering emulsion, a hydrogel, a lipogel, a single- or multi-phase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive.
  • the agents may also be in anhydrous form, such as an oil or a Balm, to be presented.
  • the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • the agents are present as microemulsions.
  • microemulsions are understood as meaning not only the thermodynamically stable microemulsions but also the so-called "PIT" emulsions, these systems being systems with the three components water, oil and emulsifier which are oil-in-water at room temperature.
  • phase inversion temperature When these systems are heated, microemulsions are formed in a certain temperature range (referred to as the phase inversion temperature or "PIT") which, on further heating, convert to water-in-oil (W / O) emulsions O / W emulsions are formed, but which are also present at room temperature as microemulsions or as very finely divided emulsions having a mean particle diameter of less than 400 nm and in particular of about 100 to 300 nm having an average particle diameter of about 200 nm. Details concerning this "P IT emulsion en” eg the publication Angew. Chem. 97, 655 - 669 (1985).
  • Lactobacillus acidophilus (DSM20242) 50ml MRS medium (composition (g / l): Peptone from casein 10.0; meat extract 8.0; yeast extract 4.0; D (+) - glucose 20.0; dipotassium hydrogen phosphate 2.0 Tween ® 80 1.0, di-ammonium hydrogen citrate 2.0, sodium acetate 5.0, magnesium sulfate 0.2, manganese sulfate 0.04) are inoculated with 2 ⁇ 10 7 cells / ml and further cultured at 37 ° C. in a 100 ml Erlenmeyer flask with shaking (100 rpm).
  • test substance w / v or v / v
  • test substance w / v or v / v
  • control without active ingredients.
  • the bacterial count was determined by plating on MRS agar (composition like MRS liquid medium but additionally with agar-agar 14 g / l).
  • MRS agar composition like MRS liquid medium but additionally with agar-agar 14 g / l.
  • the comparison of the growth in the presence of the tested active ingredients inulin and extracts of white tea, karkade (hibiscus), mallow and grape seeds
  • MRS medium composition (g / l): Peptone from casein 10.0; ® 80 1.0, di-ammonium hydrogen citrate 2.0, sodium acetate 5.0, magnesium sulfate 0.2, manganese sulfate 0.04) are inoculated with 2 ⁇ 10 7 cells / ml and further cultured at 37 ° C. in a 100 ml Erlenmeyer flask with shaking (100 rpm). Further cultivation was carried out in the presence of 1% inulin with and without the addition of 100 ppm Famesol. After 0, 8 and 24 h, the microbial count was determined by measuring the optical density at 620 nm (OD620) in the photometer. The results surprisingly show no influence on the growth of Lactobacillus acidophilus by the addition of Famesol.
  • Oil-in-water emulsions (in% by weight)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des substances actives ou des combinaisons de substances actives qui exercent une action prébiotique au niveau des parties intimes et/ou de la zone gastro-intestinale.
EP05767884A 2004-08-03 2005-07-28 Produit d'hygiene intime prebiotique Ceased EP1773328A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004037505A DE102004037505A1 (de) 2004-08-03 2004-08-03 Präbiotische Intimpflege
PCT/EP2005/008179 WO2006015726A1 (fr) 2004-08-03 2005-07-28 Produit d'hygiene intime prebiotique

Publications (1)

Publication Number Publication Date
EP1773328A1 true EP1773328A1 (fr) 2007-04-18

Family

ID=35106789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05767884A Ceased EP1773328A1 (fr) 2004-08-03 2005-07-28 Produit d'hygiene intime prebiotique

Country Status (3)

Country Link
EP (1) EP1773328A1 (fr)
DE (1) DE102004037505A1 (fr)
WO (1) WO2006015726A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006035040A1 (de) * 2006-07-28 2008-01-31 Beiersdorf Ag Wirkstoffkombinationen aus Ascorbylverbindung und hydriertem Lecithin
CN102123736A (zh) 2008-09-30 2011-07-13 亚历山大·弗拉基米罗维奇·季科夫斯基 抗真菌剂及益生元的药物组合物与念珠菌性阴道炎的治疗方法
GB2495491A (en) * 2011-05-23 2013-04-17 Bio4 Ltd Pre-biotic skin wipe
FR3009962B1 (fr) * 2013-08-28 2018-02-23 Laboratoire Herasens Compositions a base de prebiotiques et d'extraits de curculigo orchioides et leurs utilisations
CN104524455B (zh) * 2014-12-19 2018-04-27 陕西东科制药有限责任公司 一种中药复方及其在制备治疗慢性盆腔炎的药物中的应用
CN104857392A (zh) * 2015-06-05 2015-08-26 王芬 一种治疗霉菌性阴道炎的阴道栓及其制备使用方法
CN104825984A (zh) * 2015-06-05 2015-08-12 王芬 一种治疗宫颈炎的中药胶囊及其制备方法
CN104906414A (zh) * 2015-06-08 2015-09-16 山东大学齐鲁医院 一种治疗慢性宫颈炎的中药凝胶制剂
AU2017240069B2 (en) 2016-03-31 2024-03-07 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2017173240A1 (fr) 2016-03-31 2017-10-05 Gojo Industries, Inc. Composition nettoyante stimulant les peptides antimicrobiens
CN106635823B (zh) * 2016-10-19 2020-04-07 中国科学院过程工程研究所 一种控制菌丝体生长形态的方法
CA3043748A1 (fr) 2016-11-23 2018-05-31 Gojo Industries, Inc. Composition desinfectante comprenant une substance active probiotique/prebiotique
DE102017121617A1 (de) * 2017-09-18 2019-03-21 Sweat-Off Gmbh Schweisshemmende und/oder Schweißgeruch hemmende kosmetische oder pharmazeutische Zubereitungen enthaltend Aluminiumlactat und mindestens einen Pflanzenextrakt
FR3073142B1 (fr) 2017-11-07 2020-12-25 Gallinee Formulation cosmetique
WO2022219133A1 (fr) * 2021-04-16 2022-10-20 Unilever Ip Holdings B.V. Composition nettoyante pour l'hygiène intime féminine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503423A1 (de) * 1995-02-03 1996-08-08 Beiersdorf Ag Antiadhäsive Wirkstoffe
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6706287B2 (en) * 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
FR2795955A1 (fr) * 1999-07-09 2001-01-12 Oreal Compositions cosmetiques contenant un fructane cationique et un agent antipelliculaire et leurs utilisations
NZ511870A (en) * 1999-09-22 2004-02-27 Nestle Sa Method for increasing pet activity
DE10102543A1 (de) * 2001-01-19 2002-07-25 Cognis Deutschland Gmbh Emulsionen auf Basis spezieller Emulgatoren
US7829079B2 (en) * 2002-03-28 2010-11-09 Christian Hansen A/S Lactobacillus iners for the enhancement of urogenital health
US20030224034A1 (en) * 2002-05-31 2003-12-04 Koenig David W. Personal care article and method for inhibiting attachment of yeast to skin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006015726A1 *

Also Published As

Publication number Publication date
DE102004037505A1 (de) 2006-02-23
WO2006015726A1 (fr) 2006-02-16

Similar Documents

Publication Publication Date Title
EP1773328A1 (fr) Produit d'hygiene intime prebiotique
DE10333245C5 (de) Präbiotisch wirksame Pflanzenextrakte
EP1658088B1 (fr) Composition avec un effect prebiotique comprenant des extraits de pinus sylvestris et de ribes nigrum pour l'inhibition de la croissance de priopionibacterium acnes
DE102004032734A1 (de) Präbiotisch wirksame Substanzen für Deodorantien
WO2010046291A2 (fr) Utilisation d'acides hydroxycinnamiques et de leurs dérivés et/ou d'extraits végétaux pour traiter des odeurs corporelles
DE102004011968A1 (de) Präbiotisch wirksame Pflanzenextrakte
DE102005014687A1 (de) Zusammensetzung enthaltend ß-Defensin 2
WO2010031657A2 (fr) Utilisation de dérivés d'urée et de sels de phenacyl thiazolium pour le traitement d'odeurs corporelles
DE10358534A1 (de) Adhäsionshemmung von Mikroorganismen durch nichtionische Tenside
DE102009045981A1 (de) Antifalten-Kosmetikum mit Strandkamillenextrakt
WO2006076946A1 (fr) Nettoyant tensioactif comprenant des proteines specifiques
EP2322138A2 (fr) Composition antimicrobienne
US20240099955A1 (en) Skincare compositions and methods of use thereof
DE102004034691A1 (de) Verwendung von Siderophoren gegen Geruchskeime
WO2020112590A1 (fr) Extrait de centella asiatica solubilisé
JP7380111B2 (ja) 美白日焼け止め化粧料
DE102007054653A1 (de) Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
DE10340684A1 (de) Neue Verwendungen von Vitamin B6 in kosmetischen oder pharmazeutischen Zusammensetzungen
WO2023126222A1 (fr) Système antimicrobien avec alcaloïde bêta-carboline et acide phénolique et compositions les comprenant
DE10350929A1 (de) Dispirotripiperazinverbindungen zur Adhäsionshemmung von Pilzen
WO2005107874A2 (fr) Utilisation d'acide pirinixique et de ses sels pour le traitement de maladies inflammatoires chroniques
DE102004024463A1 (de) Verwendung von Ammonium-Salzen der Glyzyrrhizinsäure und der Glyzyrrhetinsäure zur Epilation
DE102007041232A1 (de) Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
EP3166588A1 (fr) Agents cosmétiques anti-transpirants avec des protéines spéciales provenant de sécrétions animales, de sécrétions d'insectes ou de sécrétions humaines, qui ne contiennent pas d'halogénures et/ou d'hydroxyhalogénures d'aluminium et/ou de zirconium

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HOEHNE, HEIDE-MARIE

Inventor name: BOCKMUEHL, DIRK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HENKEL AG & CO. KGAA

17Q First examination report despatched

Effective date: 20100202

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120614